Skip to main content

iRhythm Technologies to Participate in Upcoming Investor Conferences in September

SAN FRANCISCO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company will present at the following investor conferences in September:

  • Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, at 3:20 pm Eastern Time
  • Wells Fargo 2024 Healthcare Conference on Thursday, September 5, at 8:45 am Eastern Time
  • Baird 2024 Global Healthcare Conference on Tuesday, September 10, at 2:00 pm Eastern time

Those interested in listening to the presentations may do so by accessing the live and archived webcast of the events on the “Events & Presentations” section of the company’s investor website at investors.irhythmtech.com.

About iRhythm Technologies, Inc.
iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all.

Investor Contact
Stephanie Zhadkevich
investors@irhythmtech.com

Media Contact
Kassandra Perry
irhythm@highwirepr.com


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  239.30
-2.43 (-1.01%)
AAPL  259.48
+1.20 (0.46%)
AMD  236.73
-15.45 (-6.13%)
BAC  53.20
+0.12 (0.23%)
GOOG  338.53
-0.13 (-0.04%)
META  716.50
-21.81 (-2.95%)
MSFT  430.29
-3.21 (-0.74%)
NVDA  191.13
-1.38 (-0.72%)
ORCL  164.58
-4.43 (-2.62%)
TSLA  430.41
+13.85 (3.32%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.